Integra LifeSciences Corporation is presently staging the full market release of its Hollywood VI intervertebral body fusion device (IBD) system. According to Integra’s April 30 news release, the Hollywood VI IBD is used primarily in transforaminal lumbar interbody fusion (TLIF), a surgical procedure designed to help alleviate pain and nerve compression by fusing and stabilizing adjacent vertebrae in the lower back.
The release states that the Hollywood VI IBD incorporates a variable insertion feature, which enables surgeons to choose the appropriate delivery angle for the implant and gives more flexibility in managing varying patient anatomy. It includes a new, longer, 30mm implant that increases the bone graft volume by 33% over the current 27mm implant, and provides a larger platform to help promote spinal fusion.
IBDs are designed to help provide stability for spinal fusion after a diseased disc is surgically removed. They are small, hollow spinal implants that are inserted into the intervertebral space to restore physiological disc height and allow fusion between vertebral bodies. The graft window in the device is packed with bone and provides an environment in which natural bone growth can occur, which then enables fusion of the vertebral segments.
“Integra has developed a TLIF cage that is simple to insert, due to the variable angle insertion mechanism, while maximizing fusion rates by aggressively increasing graft space within the cage, compared to its competitors, ” said Thomas N. Scioscia, M.D., OrthoVirginia, Richmond, Virginia.
“We are always looking for ways to better serve our surgeons, ” said Kirt Stephenson, Integra’s President, U.S. Spine. “Our new Hollywood VI IBD does just that, by providing our customers with additional solutions that help meet their patients’ needs.”
